Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025

Vaxcyte, Inc.

2025-Q1 EPS reported -$1.04

Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.
VAX-24 infant Phase 2 met non-inferiority criteria for 20 of 24 serotypes; robust OPA responses.
VAX-31 infant Phase 2 advanced to second stage; adult Phase 3 non-inferiority study to start mid-2025.
New third-generation PCV candidate VAX-XL announced to further expand serotype coverage.
Dr. Olivier Brandicourt (ex-Sanofi CEO) appointed to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.